Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial.

Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ.

Acta Psychiatr Scand. 2012 Apr;125(4):342-8. doi: 10.1111/j.1600-0447.2011.01791.x. Epub 2011 Nov 12.

PMID:
22077211
2.

Medication augmentation after the failure of SSRIs for depression.

Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ; STAR*D Study Team.

N Engl J Med. 2006 Mar 23;354(12):1243-52.

3.

Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.

Gaynes BN, Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Miller WC, Stürmer T.

J Clin Psychopharmacol. 2012 Feb;32(1):114-9. doi: 10.1097/JCP.0b013e31823f705d.

PMID:
22198447
4.

Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.

Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD, Wightman DS, Modell JG.

J Clin Psychiatry. 2006 Jun;67(6):865-73.

PMID:
16848645
5.

Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?

Trivedi MH, Rush AJ, Carmody TJ, Donahue RM, Bolden-Watson C, Houser TL, Metz A.

J Clin Psychiatry. 2001 Oct;62(10):776-81.

PMID:
11816866
6.

Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression.

Lam RW, Hossie H, Solomons K, Yatham LN.

J Clin Psychiatry. 2004 Mar;65(3):337-40.

PMID:
15096072
7.

Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression.

Jamerson BD, Krishnan KR, Roberts J, Krishen A, Modell JG.

Psychopharmacol Bull. 2003 Spring;37(2):67-78.

PMID:
14566216
8.

Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC).

Ostergaard SD, Bech P, Trivedi MH, Wisniewski SR, Rush AJ, Fava M.

J Affect Disord. 2014 Jul;163:18-24. doi: 10.1016/j.jad.2014.03.049. Epub 2014 Apr 3.

PMID:
24836083
9.

Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial?

Perlis RH, Uher R, Perroud N, Fava M.

J Clin Psychiatry. 2012 Nov;73(11):1439-42. doi: 10.4088/JCP.12m07777. Epub 2012 Sep 18.

10.

A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.

Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, Thase ME, Warden D, Biggs M, Luther JF, Niederehe G, Ritz L, Trivedi MH.

Am J Psychiatry. 2006 Jul;163(7):1161-72.

PMID:
16816220
11.

An open-label trial of citalopram for major depression in patients with hepatitis C.

Gleason OC, Yates WR, Isbell MD, Philipsen MA.

J Clin Psychiatry. 2002 Mar;63(3):194-8.

PMID:
11926717
12.

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M; STAR*D Study Team.

N Engl J Med. 2006 Mar 23;354(12):1231-42.

13.

A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.

Reimherr FW, Cunningham LA, Batey SR, Johnston JA, Ascher JA.

Clin Ther. 1998 May-Jun;20(3):505-16.

PMID:
9663366
14.

Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.

Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M, Nierenberg AA, Trivedi MH.

Arch Gen Psychiatry. 2008 Aug;65(8):870-80. doi: 10.1001/archpsyc.65.8.870.

PMID:
18678792
15.

A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine.

Coleman CC, King BR, Bolden-Watson C, Book MJ, Segraves RT, Richard N, Ascher J, Batey S, Jamerson B, Metz A.

Clin Ther. 2001 Jul;23(7):1040-58.

PMID:
11519769
16.

Effects of citalopram treatment on hypothermic and hormonal responses to the 5-HT1A receptor agonist buspirone in patients with major depression and therapeutic response.

Navinés R, Martín-Santos R, Gómez-Gil E, Martínez de Osaba MJ, Imaz ML, Gastó C.

Psychoneuroendocrinology. 2007 May;32(4):411-6. Epub 2007 Mar 6.

PMID:
17337123
17.

Bupropion in the treatment of outpatients with asthma and major depressive disorder.

Brown ES, Vornik LA, Khan DA, Rush AJ.

Int J Psychiatry Med. 2007;37(1):23-8.

PMID:
17645195
18.

Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.

Zisook S, Lesser IM, Lebowitz B, Rush AJ, Kallenberg G, Wisniewski SR, Nierenberg AA, Fava M, Luther JF, Morris DW, Trivedi MH.

J Clin Psychiatry. 2011 Oct;72(10):1322-32. doi: 10.4088/JCP.10m06724.

PMID:
22075098
19.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
20.

Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.

Weihs KL, Settle EC Jr, Batey SR, Houser TL, Donahue RM, Ascher JA.

J Clin Psychiatry. 2000 Mar;61(3):196-202.

PMID:
10817105

Supplemental Content

Support Center